Extended Data Fig. 1: Stratified analysis of ciltacabtagene autoleucel (cilta-cel) vs idecabtagene vicleucel (ide-cel).
(a) Cilta-cel and ide-cel infusion dates at our institution. (b) Response rate of the entire BCMA-CART cohort, and by cilta-cel and ide-cel. Categorical variables were compared with Fisher’s exact test. (c) Progression-free survival analysis (PFS) of the entire cohort. (d) Overall survival (OS) analysis of the entire cohort. (e) Progression-free survival analysis stratified by product. Survival distributions were compared with the log-rank test. (f) Overall survival analysis stratified by product. Survival distributions were compared with the log-rank test. (g) Cytokine release syndrome (CRS) grade stratified by product. Categorical variables were compared with Fisher’s exact test. (h) Immune effector cell-associated neurotoxicity syndrome (ICANS) grade stratified by product. Categorical variables were compared with Fisher’s exact test. (i) Absolute lymphocyte count (ALC; median with interquartile range) within the first 24 days following BCMA-CART, and at Day 28, Month 3, and Month 6, stratified by product received. Data are presented as mean values ± 95% confidence interval. Statistical comparisons between groups were performed using the two-tailed Wilcoxin test. Exact P-values are provided in Supplementary Table S9. (j) Peak absolute lymphocyte count (ALCPeak) at apheresis, Day 0, Day 7, Day 14, and Day 21 stratified by product. Data are presented as median values ± interquartile range. Statistical comparisons between groups were performed using the two-tailed Wilcoxin test. Exact P-values are provided in Supplementary Table S9. (k) CD4+ and CD8+ proportion of T-cells at apheresis, Days 7 and 28, Months 3 and 6 post-BCMA-CART, stratified by product. Bar graphs show the median and the error bars denote the 25th and 75th percentiles (top). Area under the curve (AUC) analysis of CD4⁺ T-cell proportions from apheresis to Month 6 in the cilta-cel cohort, stratified by product. Data are shown as median values with error bars representing the 25th and 75th percentiles. Shaded regions indicate the area under the curve (AUC) for each group (bottom). Statistical comparisons between groups were performed using the two-tailed Wilcoxin test. * Indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001. (l) Non-relapse mortality of the entire cohort. (m) Non-relapse mortality analysis stratified by product. Survival distributions were compared with the log-rank test. ALCPeak: peak absolute lymphocyte count; AUC: area under curve; CART: CAR T-cell; cilta-cel: ciltacabtagene-autoleucel; CI: confidence interval; CirAE: CART-associated immune-related adverse events; CRS: cytokine release syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome; NRM: non-relapse mortality; ORR: overall response rate; OS: overall survival; ide-cel: idacabtagene-vicleucel; PFS: progression free survival; ≥ VGPR: very good partial response or better.
